You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Y2 and Y4 Agonists in Obesity

    SBC: P2D, INC            Topic: NIDDK

    DESCRIPTION (provided by applicant): The purpose of the proposed studies is to assess the feasibility of developing a novel Neuropeptide Y (NPY) obesity treatment. Extensive preclinical and clinical studies indicate that NPY receptors are important mediators of appetite and obesity. The proposed Specific Aims will determine if chronic treatment with selective NPY Y2 or Y4 receptor agonists demonst ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  2. XT-101: A Potent IL-10 Based Therapy for Treating Multiple Sclerosis.

    SBC: XALUD THERAPEUTICS, INC.            Topic: NINDS

    DESCRIPTION (provided by applicant): Xalud Therapeutics proposes to evaluate the applicability of its novel and potent anti-inflammatory therapy, XT-101, for the treatment of motor impairment, gait disorders, and neuropathic pain in degenerative and inflammatory autoimmune rodent models of multiple sclerosis (MS). XT-101 is a non-viral form of gene therapy that causes the meningeal cells surround ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Wound Decontamination for the Prevention and Treatment of Multi-drug Resistant Ba

    SBC: SYNEDGEN, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): The frequency of multi-drug resistant infections is increasing at an alarming rate. Equally concerning is the limited therapeutic options available for effective treatment, resulting in increased morbidity and mortality associated with these highly resistant infections. Frequently, multi-drug resistant infections manifest as soft tissue or wound infections caus ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  4. Wiring Adolescents With Social Anxiety via Behavioral Interventions (WASABI): a closed-loop mobile intervention to reduce social anxiety and improve social skills

    SBC: Posit Science Corporation            Topic: 104

    PROJECT SUMMARY The goal of this project is to further developto pivotal trial readinessand evaluate WASABIWiring Adolescents With Social Anxiety via Behavioral Interventionsa clinician assistedadjunct to treatmentmobile application designed to augment the efficacy of psychological Evidence Based Treatments through a closed loop technologyIn this projectwe will build upon promising results obtaine ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Wireless Sensor Inserts for Combating Incontinence-Associated Dermatitis

    SBC: WELLSPRING BIOSCIENCES, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): The development of drugs that inhibit the K-Ras oncogene represents one of the greatest unmet needs in the treatment of human cancer. The Ras gene is the most frequently mutated oncogene in cancer, with a greater than 30% cumulative mutation frequency across all cancer types. Cancers with Ras mutations are aggressive and respond poorly to standard therapies. Pr ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  6. Wirelessly Observed Therapy to Monitor Treatment of Mycobacterium Tuberculosis

    SBC: PROTEUS DIGITAL HEALTH, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Eradication of Mycobacterium Tuberculosis (MTB) has been a major goal of the CDC, the Global Alliance on TB, and the WHO for decades. Poor adherence to therapy has long been a recognized barrier to effective treatment of MTB infection. Inconsistent and interrupted treatment has led to rising numbers of MTB cases and the emergence of drug resistant MTB. One thir ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Whole Blood Filter Paper Assay for Alzheimers Disease

    SBC: BioSpyder Technologies, Inc.            Topic: NIA

    Summary In this Phase I program we will establish the feasibility of a novel filter paper whole blood sample based targeted sequencing assay based on the TempO Seqplatform to measure DNA and RNA profiles as the basis for the development of a minimally invasive prognostic diagnostic assay of Alzheimer s DiseaseADWe will use our already functional whole transcriptome targeted gene expression assay t ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Whiteboard Coordinator: Intelligent Sensor Network and Machine Learning to Improve Operating Room Outcomes and Efficiency

    SBC: Artisight, Inc.            Topic: NLM

    Hospital operating roomsORare currently under tremendous pressure to maximize patient outcomes and safety while reducing costsHospitals that focus on disadvantaged socioeconomic populations are often further burdened to meet these growing demands with a significant lack of resourcesThe U Sspent $trillion on healthcare inwithcomprised of healthcare worker wagesUnlike virtually all other sectorsheal ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Well-Flushed Hydrodynamic Bearing for Miniature Blood Pumps

    SBC: Perfusion Solutions, Inc.            Topic: NHLBI

    Ventricular assist devicesVAD sclearly have a role in cardiac medicinehow to precisely define that role is still subject to research and debateconsidering the possibilities of destination therapybridge to transplantbridge to recoverybridge to definitive therapy and possibly other variants one might specifyCertain VAD features are emerging as requiredadequate output to truly make a difference to th ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Web-based Phenotyping for Genome Wide Association Studies of Drug Response

    SBC: 23ANDME, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Greater availability of personalized genetic information regarding the efficacy or toxicity of medications could lead to improved patient care and save consumers, insurers and medical institutions billions of dollars per year. Although the field of pharmacogenomics has had some success in discovering relationships between genetic variants and drug response, a g ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government